The Top 5 Biosimilar Articles for the Week of August 31

September 4, 2020

Here are the top 5 biosimilar articles for the week of August 31, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 31, 2020.

Number 5: British Columbia's Pharmacare prescription coverage plan entered into its third phase of the program this month, where enrolled residents who are receiving reference rituximab will be switched to 1 of 3 biosimilar versions.

Number 4: Lupin Limited and Mylan have launched the biosimilar etanercept Nepexto in Germany for the treatment of several inflammatory diseases.

Number 3: Biocon Biologics and Mylan said they have launched the long-acting insulin glargine product Semglee on the US market and hope to obtain formal biosimilar status for it.

Number 2: Continuing with its string of recent biosimilar launches, Cadila Pharmaceuticals has put an adalimumab biosimilar (Cadalimab) on the Indian market.

Number 1: As the global pandemic cases topped 25 million by late summer 2020, many biosimilar manufacturers had joined the fight to find treatments for coronavirus disease 2019 (COVID-19).

To read all of these articles and more, visit centerforbiosimilars.com.


x